肾衰Ⅱ号方对慢性肾脏病3-4期轻中度蛋白尿患者影响的临床研究
Clinical study on the effect of Shenshuai Ⅱ Decoction on chronic kidney diseases 3-4 stages patients with mild-to-moderate proteinuria
- 上海中医药杂志 2021年55卷第2期 页码：71-75
- 作者机构：
1.上海中医药大学附属曙光医院肾病科，上海中医药大学中医肾病研究所，上海市中医临床重点实验室，肝肾疾病病证教育部重点实验室（上海 201203）
- 作者简介：
杨婧，女，博士，主治医师，主要从事中医药防治慢性肾脏病的临床研究工作
王琛，博士，主任医师；E-mail：chenwang42@163.com
- 基金信息：上海市卫计委进一步加快中医药事业发展三年行动计划项目(ZY（2018-2020）-CCCX-2003-08;ZY（2018-2020）-FWTX-7005);上海市卫计委科研课题(20174Y0162);上海市浦东新区卫生系统重点学科群建设项目(PWZxq2017-07)
DOI：10.16305/j.1007-1334.2021.2009106
中图分类号：
扫 描 看 全 文
杨婧, 邹赟, 吴琪琪, 等. 肾衰Ⅱ号方对慢性肾脏病3-4期轻中度蛋白尿患者影响的临床研究[J]. 上海中医药杂志, 2021,55(2):71-75.
Jing YANG, Yun ZOU, Qiqi WU, et al. Clinical study on the effect of Shenshuai Ⅱ Decoction on chronic kidney diseases 3-4 stages patients with mild-to-moderate proteinuria[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(2):71-75.
杨婧, 邹赟, 吴琪琪, 等. 肾衰Ⅱ号方对慢性肾脏病3-4期轻中度蛋白尿患者影响的临床研究[J]. 上海中医药杂志, 2021,55(2):71-75. DOI： 10.16305/j.1007-1334.2021.2009106.
Jing YANG, Yun ZOU, Qiqi WU, et al. Clinical study on the effect of Shenshuai Ⅱ Decoction on chronic kidney diseases 3-4 stages patients with mild-to-moderate proteinuria[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(2):71-75. DOI： 10.16305/j.1007-1334.2021.2009106.
摘要
目的,2,观察肾衰Ⅱ号方对慢性肾脏病（CKD）3-4期轻中度蛋白尿患者的影响。,方法,2,将88例CKD3-4期轻中度蛋白尿患者，随机分为治疗组和对照组，每组44例。两组均予基础治疗，对照组加用尿毒清颗粒，治疗组加用肾衰Ⅱ号方。两组疗程均为6个月，观察临床疗效，比较两组中医症状积分、血肌酐（Scr）、尿素氮（BUN）、肾小球滤过率（eGFR）、24h尿蛋白定量（24hUpro）、尿视黄醇结合蛋白（RBP）、尿α1微球蛋白（α1-MG）、尿β2-微球蛋白（β2-MG）的变化情况。,结果,2,①治疗组、对照组临床总有效率分别为86.36%、61.36%；组间临床疗效比较，治疗组优于对照组（,P,<,0.05）。②治疗前后组内比较，治疗组中医症状各分项积分及总分均较治疗前明显下降（,P,<,0.05），对照组除面色晦暗、恶心呕吐外，其余症状各分项积分及总分明显下降（,P,<,0.05）；组间治疗后比较，除口干口苦外，治疗组症状各分项积分及总分均低于对照组（,P,<,0.05）。③治疗前后组内比较，治疗组Scr、BUN明显下降（,P,<,0.05），eGFR明显上升（,P,<,0.05），对照组Scr明显下降（,P,<,0.05）；组间治疗后比较，治疗组BUN较对照组明显下降（,P,<,0.05）。④治疗前后组内比较，治疗组24hUpro、尿β2-MG、尿α1-MG、尿RBP均明显下降（,P,<,0.05），对照组24hUpro、尿α1-MG明显下降（,P,<,0.05）；组间治疗后比较，治疗组尿β2-MG、尿α1-MG、尿RBP明显低于对照组（,P,<,0.05）。,结论,2,肾衰Ⅱ号方治疗CKD3-4期轻中度蛋白尿的临床疗效优于尿毒清颗粒，能显著改善患者的中医症状、肾功能及肾小管性尿蛋白水平，延缓慢性肾脏病的进展。
Abstract
Objective,2,To observe the effect of Shenshuai Ⅱ Decoction on chronic kidney diseases (CKD) 3-4 patients with mild-to-moderate proteinuria.,Methods,2,A total of 88 patients of CKD3-4 stages with mild-to-moderate proteinuria were randomly divided into control group (44 cases) and treatment group (44 cases). On the basic treatment, the treatment group was treated with Shenshuai Ⅱ Decoction, and the control group was treated with Niaoduqing Granule. The course of treatment in both groups was 6 months. The clinical efficacy and TCM symptom score, renal function (Scr, BUN, eGFR), urine protein (24hUpro, URBP, Uα1-MG, Uβ2-MG)were observed., Results,2,①The total effective rate was 86.36% in the treatment group and 61.36% in the control group, and the clinical efficacy in the treatment group was better than that in the control group(,P,<,0.05). ②After treatment, the single scores and the total scores of TCM symptoms in the treatment group were significantly decreased (,P,<,0.05), while those in the control group were significantly decreased except dark complexion, nausea and vomiting (,P,<,0.05). Except dry mouth and bitter mouth, the single scores and the total scores of TCM symptoms in the treatment group were lower than those in the control group (,P,<,0.05).③After treatment, the levels of Scr and BUN were significantly decreased, and the eGFR level was significantly increased in the treatment group (,P,<,0.05). In the control group, the level of Scr was significantly decreased (,P,<,0.05). The level of BUN was lower in the treatment group than that in the control group (,P,<,0.05). ④After treatment, the levels of 24hUpro, Uβ 2-MG, Uα 1-MG and URBP significantly decreased in the treatment group (,P,<,0.05), while 24hUpro and Uα1-MG decreased significantly in the control group (,P,<,0.05). The levels of Uβ 2-MG, Uα 1-MG and URBP were lower in the treatment group than those in the control group(,P,<,0.05).,Conclusion,2,Shenshuai Ⅱ Decoction has better clinical efficacy than Niaoduqing Granule in the treatment of CKD3-4 patients with mild-to-moderate proteinuria, which significantly improves TCM symptoms and renal function, reduces the level of tubular proteinuria, and delays the progression of CKD.
关键词
慢性肾脏病肾衰Ⅱ号方蛋白尿肾功能临床试验
Keywords
chronic kidney diseaseShenshuai Ⅱ Decoctionproteinuriarenal functionclinic trial
references
PETERSON J C, ADLER S, BURKART J M, et al. Blood pressure control, proteinuria, and the progression of renal disease: the modification of diet in renal disease study[J].Ann Intern Med,1995,123(10): 754-762.
杨婧，严睿俊，王琛. 肾衰Ⅱ号方对慢性肾脏病患者肾功能及炎症因子的影响[J].中国中医药信息杂志,2014,21(12): 15.
WANG M, YANG J, ZHOU Y, et al. ShenShuai Ⅱ recipe attenuates apoptosis and renal fibrosis in chronic kidney disease by increasing renal blood flow and improving oxygen consumption[J].Evid Based Compl Alt,2018(2018): 1-8.
周圆，王琛，何立群，等. 肾衰Ⅱ号方治疗CKD 3-4期患者的临床疗效观察[J].上海中医药大学学报,2011,25(4): 37-40.
KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease[J].Am J Kidney Dis,2007,49(Suppl 2): S12-S154.
国家药品监督管理局. 中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002: 233-236.
PRABHAKARAN D, ANAND S, WATKINS D, et al. Cardiovascular, respiratory, and related disorders: Key messages from Disease Control Priorities[J].Lancet,2018,391(3): 1224-1236.
XIE Y, BOWE B, MOKDAD A H, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016[J].Kidney Int,2018(94): 567-581.
GLASSOCK R J, WARNOCKD G, DELANAYE P. The global burden of chronic kidney disease: Estimates, variability and pitfalls[J].Nat Rev Nephrol,2017(13): 104-114.
LV J C, ZHANG L X. Prevalence and disease burden of chronic kidney disease[J].Adv Exp Med Biol,2019(1165): 3-15.
OLIVEIRA E A, MAK R H. Progression of chronic kidney disease in children-role of glomerular hemodynamics and interstitial fibrosis[J].Curr Opin Pediatr,2018(30): 220-227.
COZZOLINO M, GENTILE G, MAZZAFERRO S, et al. Blood pressure, proteinuria, and phosphate as risk factors for progressive kidney disease: a hypothesis[J].Am J Kidney Dis,2013,62(5): 984-992.
关子赫，李敬孝. 李敬孝治疗慢性肾功能衰竭蛋白尿验案介绍[J].新中医,2015,47(2): 290-291.
祝婷婷，王琛. 郑平东论治慢性肾炎蛋白尿经验拾萃[J].辽宁中医杂志,2016,43(1): 34-35.
贾安奎，许光霞，刘彦轩. 尿单核细胞趋化蛋白1和尿视黄醇结合蛋白与糖尿肾病的关系[J].中国糖尿病杂志,2010,18(12): 907-909.
AWAD H, EL-BARBARY M, IMAM S, et al. Evaluation of renal glomerular and tubular functional and structural integrity in neonates[J].Am J Med Sci,2002,324(5): 261-266.
0
浏览量
301
下载量
0
CSCD
5
CNKI被引量
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 沪ICP备13044091号
沪公网安备 31011502015228号 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
- 总访问量：70551 今日访问量：32